SOLP - Guidelines for Diagnosis and Monitoring of Hepatitis



1. Adolph L, Lorenz R. Enzyme diagnosis in diseases of the heart, liver, and pancreas. New York, S Karger Co., 1982,9-27.

2. Jung K, Mildner D, Jacob B, et al. On the pyridoxal-5'-phosphate stimulation of AST and ALT in serum and erythrocytes of patients undergoing chronic hemodialysis and with kidney transplants. Clin Chim Acta 1981;115:105-110.

3. Wroblewski F. The clinical significance of alterations in transaminase activities of serum and other body fluids. Adv Clin Chem 1958;1:313-351.

4. Lott JA, Wolf PL. Alanine and aspartate aminotransferase (ALT and AST). Clinical enzymology: a case-oriented approach. Chicago, Year Book Medical Publishers, 1986,111-138.

5. Rej R. Measurement of aminotransferases: Part 1. Aspartate aminotransferase. CRC Crit Rev Clin Lab Sci 1984;21:99-106.

6. Price CP, Alberti KGMM: Biochemical Assessment of Liver Function. in Wright R, Alberti KGMM, Karran S, Millward-Sadler GH (eds.): Liver and Biliary Disease – Pathophysiology, Diagnosis, Management. London: W.B. Saunders, 1979,381-416.

7. Panteghini M: Aspartate aminotransferase isoenzymes. Clin Biochem 1990;23:311-319.

8. Siest G, Schiele F, Galteau M-M, et al.: Aspartate aminotransferase and alanine aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975;21:1077-1087.

9. Manolio TA, Burke GL, Savage PJ, et al.: Sex- and race-related differences in liver-associated serum chemistry tests in young adults in the CARDIA study. Clin Chem 1992;28:1853-1859.

10. Salvaggio A, Periti M, Miano L, Tavanelli M, Mazurati D: Body mass index and liver enzyme activity in serum. Clin Chem 1991;37:720-723.

11. Nuttall FQ, Jones B: Creatine kinase and glutamic oxolacetic transaminase activity in serum: kinetics of change with exercise and effect of physical conditioning. J Lab Clin Med 1968;51:257-261.

12. Dufour DR: Effects of habitual exercise on routine laboratory tests. Clin Chem 1998;44:A136.

13. Zhou S-L, Gordon RE, Bradbury M, Stump D, Kiang C-L, Berk PD: Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in Hep G-2 cells. Hepatology 1998;27:1064-1074.

13a. Litin S, O’Brien JF, Pruett S, et al.: Macroenzyme as a cause of unexplained elevation of aspartate aminotransferase. Mayo Clin Proc 1987;62:681-687.

13b. Mifflin TE, Bruns DE, Wrotnoski U, et al.: Macroamylase, macro creatine kinase, and other macroenzymes. Clin Chem 1985;31:1743-1748.

14. Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem 1978;24:58-73.

15. Vanderlinde RE: Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci 1986;16:79-93.

16. Allman MA, Pang E, Yau DF, Stewart PM, Tiller DJ, Truswell AS: Elevated plasma vitamers of vitamin B6 in patients with chronic renal failure on regular hemodialysis. Eur J Clin Nutr 1992;46:679-683.

17. AST and ALT. College of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry Survey 1997,15-18 (AST), 7-10 (ALT).

18. Posen S. Studies in human alkaline phosphatases. M.D. thesis, University of Adelaide, Australia, 1966.

19. Posen S. Alkaline phosphatase. Ann Intern Med 1967; 67:183-194.

20. Fishman WH, Ghosh NE. Isoenzymes of human alkaline phosphatase. Adv Clin Chem 1976; 10:255-370.

21. Kaplan MM. Alkaline phosphatase N Engl J Med 1972;62:452-468.

22. Crofton PM. Biochemistry of alkaline phosphatase isoenzymes. Crit Rev Clin Lab Sci 1982;16:161-194.

23. McComb RB, Bowers GN Jr, Posen S. Alkaline phosphatase. New York, Plenum Press, 1979;525-786.

24. Moss DW. Multiple forms of acid and alkaline phosphatases: genetics, expression and tissue modification. Clin Chim Acta 1986;161:123-135.

25. Weiss MJ, Ray K, Henthorn PS, et al. Structure of the human liver/bone/kidney alkaline phosphatase gene. J Biol Chem 1988;263:12002-12010.

26. Clubb JS, Neale FC, Posen S. The behavior of infused placental alkaline phosphatase in human subjects. J Lab Clin Med 1965;66:493-507.

27. Kleerekoper M, Horne M, Cornish CJ, et al. Serum alkaline phosphatase after fat ingestion. Clin Sci 1970;38:339-341.

28. Posen S, Grundstein HS. Turnover of skeletal alkaline phosphatase in humans. Clin Chem 1982;28:153-154.

29. Dufour, DR: Gender related differences in liver function and integrity tests. Clin Chem 1998;44:A137.

30. Bayer PM, Hotschek H, Knoth E. Intestinal alkaline phosphatase and the ABO blood group system: A new aspect. Clin Chim Acta 1980;108:81-7.

31. Dufour, DR: Effects of oral contraceptives on routine laboratory tests. Clin Chem 1998;44:A137.

32. Moss DW. Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. Clin Chim Acta 1997;257:133-140.

33. Schaeler R. The mechanism of the increase in the activity of liver alkaline phosphatase in experimental cholestasis: measurement of an increased enzyme concentration by immunochemical titration. Z Klin Chem Klin Biochem 1975;13:277-281.

34. Schlaeger R, Haux D, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. Enzyme 1982;28:3-13.

35. Epstein E, Kiechle F, Zak B. Use of alkaline phosphatase isoenzymes analysis in the evaluation of cholestatic liver disease. Ann Clin Lab Sci 1984;14:292-297.

36. Griffiths J. An alternate origin for the placental isoenzyme of alkaline phosphatase. Arch Pathol Lab Med 1992;116:1019-1024.

37. Bowers GN Jr, McComb RB, Kelley ML. Measurement of total alkaline phosphatase activity in human serum. Sel Meth Clin Chem 1977;8:31-9.

38. Bowers GN Jr, McComb RB. Measurement of total alkaline phosphatase activity in human serum. Clin Chem 1975;21:1988-1995.

39. Alkaline phosphatase. College of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry Survey, 1997,11-14.

40. Gomez B, Ardakani S, Ju J, et al. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1551-1553.

41. Martin M, Van Hoof V, Couttenye M, et al. Analytical and clinical evaluation of a method to quantify bone alkaline phosphatase, a marker of osteoblastic activity. Anticancer Res 1997;17:3167-3170.

42. Woitge HW, Seibel MJ, Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases. Clin Chem 1996;42:1796-1804.

43. Chowdhury JR, Wolkoff AW, Chowdhury NR, Arias IM. Hereditary jaundice and disorders of bilirubin metabolism. In: The metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngaarden JB, Fredrickson DS, eds., New York, McGraw-Hill, Inc., 1995;2:2161-2208.

44. Berk PD, Noyer C. Clinical chemistry and physiology of bilirubin. Sem Liver Dis 1994;14:346-351.

45. Bloomer JR, Berk PD, Vergalla J, Berlin NI. Influence of albumin on the extravascular distribution of unconjugated bilirubin. Clin Sci Mol Med 1973;45:517-521.

46. McDonagh AF, Palma AA, Lauff JJ, Wu TW: Origin of mammalian biliprotein and rearrangement of bilirubin glucuronides in vivo in the rat. J Clin Invest 1984;74:763-770.

47. Fevery J, Blanckaert N: What can we learn from analysis of serum bilirubin. J Hepatol 1986;2:113-121.

48. Notter D. Bilirubin. In: Interpretation of clinical laboratory tests, Siest G, Schiele F, Henny J, Young DS, eds. Foster City, CA, Biomedical Publications, 1985,146-163.

49. Carmel R, Wong ET, Weiner JM, Johson CS. Racial differences in serum total bilirubin levels in health and in disease (pernicious anemia). JAMA 1985;253:3416-3418.

50. Dufour, DR: Effects of food ingestion on routine laboratory tests. Clin Chem 1998;44:A136.

51. Van Hootegem P, Fevery J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison with other liver function tests and changes in the portobstructive period. Hepatology 1985;5:112-117.

52. Bosma PJ, Chowdhury JR, Gantla BC, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's Syndrome. N Engl J Med 1995;333:1171-1175.

53. Thomsen HF, Hardt F, Juhl E. Diagnosis of Gilbert's Syndrome. Scand J Gastroent 1981;16:699-703.

54. Lo DH, Wu TW: Assessment of the fundamental accuracy of the Jendrassik-Grof total and direct bilirubin assays. Clin Chem 1983;29:31-36.

55. ArvanD, Shirey TL: Conjugated bilirubin: a better indicator of impaired hepatobiliary excretion than direct bilirubin. Ann Clin Lab Sci 1984;15:252-259.

56. Doumas BT, Wu T-W, Jendrzejcaz: Delta bilirubin: absorption spectra, molar absorptivity, and reactivity in the diazo reaction. Clin Chem 1987;33:769-774


57. Doumas BT, Wu T-W. The measurement of bilirubin fractions in serum. Crit Rev Clin Lab Sci 1991;28:415-446.

58. Ihara H, Shino Y, Hashizume N, et al. Effect of light on total and direct bilirubin by an enzymatic bilirubin oxidase method. J Anal Bio Sci 1997;20:349-354.

59. Kubasik NP, Mayer TK, Bhaskar AG, Sine HE, D’Souza JP: The measurement of fractionated bilirubin by Ektachem film slides – method validation and comparison of conjugated bilirubin measurements with direct bilirubin in obstructive and hepatocellular jaundice. Am J Clin Pathol 1985;84:518-523.

60. Total bilirubin. College of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry Survey 1997,18-20.

61. Binder L, Smith D, Kupka T, et al.: Abnormalities of urine urobilinogen and urine bilirubin assays and their relation to abnormal results of serum liver function tests. South Med J 1988;81:1229-1232.

62. Binder L, Smith D, Kupka T., et al.: Failure of prediction of liver function test abnormalities with the urine urobilinogen and urine bilirubin assays. Arch Pathol Lab Med 1989;.113:73-76.

63. Miura T, Matsuda Y, Tsue A, et al. Immunological cross-reactivity of gamma-glutamyl transpeptidase from human and rat kidney. J Biochem (Tokyo) 1981;89:217-222.

64. Tate SS, Meister A. Gamma-glutamyl transpeptidase: catalytic, structural and functional aspects. Mol Cell Biochem 1981; 39:357-368.

65. Jung K, Wischke UW. Electrophoretic variants of alanine aminopeptidase, alkaline phosphatase, and gamma-glutamyl transferase in urine. Clin Chem 1984;30:856-859.

66. Meister A, Anderson ME. Glutathione. Ann Rev Biochem 1983;52:711-760.

67. Leino A, Impivaara O, Irjala K, Maki J, Peltola O, Jarvisalo J: Health-based reference intervals for ALAT, ASAT, and GT in serum, measured according to the recommendations of the European Committee for Clinical Laboratory Standards (ECCLS). Scand J Clin Lab Invest 1995;55:243-250.

68. Nilssen O, Helge-Forde O, Brenn T: The Tromso study – distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990;132:318-326.

69. Schiele F. Guilmin A-M, Detienne H, et al. Gamma-glutamyltransferase activity in plasma: statistical distributions, individual variations, and reference intervals. Clin Chem 1977;23:1023-1028.

69a. Combes B, Shore GM, Cunningham FG, Walker FB, Shorey JW, Ware A: Serum gamma-glutamyl transpeptidase activity in viral hepatitis: suppression in pregnancy and by birth control pills. Gastroenterology 1977;72:271-274.

70. Aldenhovel HG: The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. Eur Arch Psychiatry Neurol Sci 1988;237:312-316.

71. Sheeman M, Maythorn P. Predictive value of gamma-glutamyl transpeptidase in various liver diseases. In: Goldberg DM, Werner M, eds. Progress in Clinical Enzymology, New York, Masson, 1979,184-187.

72. Ratanasavanh D, Tazi A, Gaspart E. Hepatic gamma-glutamyl transferase release: effect of bile salt and membrane structure modification. Advan Biochem Pharamacol 1982;3:93-103.

72a. Anciaux ML, Pelletier AG, Attali P, Meduri B, Liguory C, Etienne JP: Prospective study of clinical and biochemical features of symptomatic choledocholithiasis. Dig Dis Sci 1986;31:449-453.

72b. Itoh S, Nakajima M: Liver gamma-glutamyl transferase activity in viral liver disease. Digestion 1986;33:121-125.

73. Schmidt E, Schmidt FW: Progress in the enzyme diagnosis of liver disease: reality or illusion. Clin Biochem 1990;23:375-283.

73a. Nemesanszky E, Lott JA: Gamma-glutamyltransferase and its isoenzymes: progress and problems. Clin Chem 1985;31:797-803.

73b. Betro MG. Oon RC, Edwards JB: Gamma-glutamyl transpeptidase in diseases of the liver and bone. Am J Clin Pathol 1973;60:672-678.

74. Kim NK, Yasmineh WG, Freier EF, et al. Value of alkaline phosphatase, 5'-nucleotidase, gamma-glutamyltransferase, and glutamate dehydrogenase activity measurements (single and combined) in serum in diagnosis of metastasis to the liver. Clin Chem 1977;23:2034-2038.

75. Whitehead TP, Clarke CA, Whitfield AGW: Biochemical and haematological markers of alcohol intake. Lancet 1978;1:978-981.

76. Belfrage P, Berg B, Hagerstrand I, Nilsson-Ehle P, Tornqvist H, Wiebe T: Alterations of lipid metabolism in healthy volunteers during long-term ethanol intake. Eur J Clin Invest 1977;127:127-131.

77. Moussavian SN, Becker RC, Piepmeyer JL, Mezey E, Bozian RC: Serum gamma-glutamyl transpeptidase and chronic alcoholism – influence of alcohol ingestion and liver disease. Dig Dis Sci 1985;30:211-214.

78. Hedworth-Whitty RB, Whitfield JB, Richardson RW. Serum gamma-glutamyltranspeptidase activity in myocardial ischaemia. Brit Heart J 1967;29:432-438.

79. Goldberg DM. Functional and clinical aspects of gamma-glutamyltranspeptidase and its isoenzymes: a critical review of recent progress. In: Griffiths JC, Clinical enzymology, New York, Masson Publishing USA, Inc., 1979,123-154.

79a. Burrows S, Feldman W, McBride F: Serum gamma-glutamyl transpeptidase. Evaluation in screening of hospitalized patients. Am J Clin Pathol 1975;64:311-314.

80. Shaw LM, Stromme JH, London JL, Theodorsen L: International Federation of Clinical Chemistry. Scientific Committee, Analytical Section. Expert Panel on Enzymes. IFCC methods for measurement of enzymes. Part 4. IFCC methods for gamma- glutamyltransferase [(gamma-glutamyl)-peptide: amino acid gamma- glutamyltransferase, EC]. Clin Chim Acta 1983;135:315f-338f.

81. Gamma glutamyl transferase. College of American Pathologists, 325 Waukegan Road, Northfield, IL 60093, Chemistry Survey 1997,33-34.

82. Ts’ao C, Swedlund J, Neofotistos D: Implications of use of low international sensitivity index thromboplastins in prothrombin time testing. Arch Pathol Lab Med 1994;118:1183-1187.

83. Peters RH, van den Besselaar AMHP, Olthuis FM: Determination of the mean normal prothrombin time for assessment of international normalized ratios. Usefulness of lyophilized plasma. Thromb Haemost 1991;66:442-445.

84. WHO Expert Committee on Biological Standardization. 33rd Report. World Health Organ Tech Rep Ser 1983;687:81-105.

85. Taberner DA, Poller L, Thomson JM, Darby KV: Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalised ratios (INR). J Clin Pathol 1989:42:92-96.

86. Johnson M, Harrison L, Moffatt K, Wilian A, Hirsh J: Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med 1996;128:214-217.

87. Kovacs MJ, Wong A, MacKinnon K, et al.: Assessment of the validity of the INR system for patients with liver impairment. Thromb Haemost 1994;71:727-730.

88. Robert A, Chazouilleres O: Prothrombin time in liver failure: time, ratio, activity percentage, or International Normalized Ratio? Hepatology 1996;24:1392-1394.

88a. Robert A, Chazouilleres O: Prothrombin time in liver failureA: time, ratio, activity percentage, or international normalized ratio? Hepatology 1996;24:1392-1394.

88b. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B: Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981;305:242-248.

89. Van den Besselaar AMHP, Halem-Visser LP, Loeliger EA: The use of evacuated tubes for blood collection in oral anticoagulant control. Thromb Haemost 1983;40:676-677.

90. Raskob GE, Durica SS. Owen WL, Comp PC: Monitoring low-dose warfarin therapy by a central laboratory and implications for clinical trials and patient care: the Coumadin Aspirin Reinfarctin (CARS) Pilot Study Group. Am J Cardiol 1996;78:1074-1076.

91. Baglin T, Luddington R: Reliability of delayed INR determination: implications for decentralized anticoagulant care with off-site blood sampling. Br. J. Haematol 1997;96:431-434.

92. Fairweather RB, Ansell J, van den Besselaar AMHP, et al.: College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy – laboratory monitoring of oral anticoagulant therapy. Arch Pathol Lab Med 1998;122:768-781.

93. Dwyre AL, Giles AR, Key LA, Butler JR, Beck LR, Callahan JB: The effects of sodium citrate anticoagulant concentration, storage on or off cellular matrix, and specimen age on prothrombin time INR using a low ISI (1.06) rabbit brain thromboplastin. Thromb Haemost 1995;73:1237.

94. Adcock DM, Kressen DC, Marlar RA: Effect of 3.2% vs. 3.8% sodium citrate on routine coagulation testing. Am J Clin Pathol 1997;107:105-110.

95. Dufour, DR, Teot, L: Laboratory identification of ischemic hepatitis (shock liver). Clin Chem 34: 1287, 1988.

96. Fuchs S, Bogomolski-Yahalom V, Paltiel O, Ackerman Z: Ischemic hepatitis: clinical and laboratory observations of 34 patients. J Clin Gastroenterol 1998;26:183-186.

97. Singer AJ, Carracio TR, Mofenson HC: The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction. Ann Emerg Med 1995;26:49-53.

98. Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B: Serious hepatitis A: an analysis of patients hospitalized during an epidemic in the United States. Ann Intern Med 1998;128:111-114.

99. Mendenhall CL and the VA Cooperative Study Group on Alcoholic Hepatitis: Alcoholic hepatitis. Clin Gastroenterol 1981;10:417-441.

100. O’Grady JG, Alexander GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:4439-4445.

101. Bonacini M, Hadi G, Govindarajan S, Lindsay KL: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection. Am J Gastroneterol 1997;92:1302-1304.

102. Poller L, Triplett DA, Hirsh J, Carroll J, Clarke K: The value of plasma calibrants in correcting coagulometer effects on international normalized ratios – an international multicenter study. Am J Clin Pathol 1995;103:358-365.

103. Davis KD, Danielson CFM, May LS, Han Z-Q: Use of different thromboplastin reagents causes greater variability in international normalized ratio results than prolonged room temperature storage of specimens. Arch Pathol Lab Med 1998;122:972-977.

104. Cunningham MTA, Johnson GF, Pennell BJ, Olson JD: The reliability of manufacturer-determined, instrument specific international sensitivity index values for calculating the international normalized ratio. Am J Clin Pathol 1994;102:128-133.

105. Stevenson KJ, Craig S, Dufty JMK, Taberner DA: System ISI calibration: a universally applicable scheme is possible only when coumarin plasma calibrants are used. Br J Haematol 1997;96:435-441.

106. Taberner DA, Poller L, Thompson JM, Darby KV: Effect of international sensitivity index (ISI) of thromboplastins on precision of international normalized ratios (INR). J Clin Pathol 1989;42:92-96.

107. Kitchen S, Walker ID, Woods TAL, Preston FE: Thromboplastin related differences in the determination of international normalized ratio: a cause for concern? Thromb Haemost 1994;72:426-429.

108. Lassen JF, Kjeldsen J, Antonsen S, Petersen PH, Brandslund I: Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy. Clin Chem 1995;41:1171-1176.

109. Poller L: Screening INR deviation of local prothrombin time systems. J Clin Pathol 1998;51:356-359.

110. Johnson M, Brigder M: A cross-Canada survey of prothrombin time testing – does the establishment of local ISI values improve the accuracy of International Normalized Ratio reporting? Am J Clin Pathol 1998;110:683-690.

110a. Stapleton JT: Host immune response to hepatitis A virus. J Infect Dis 1995;175(Suppl 1):S9-S14.

111. Lemon SM, Brown CD, Brooks DS, Simms TE, Bancroft WH: Specific immunoglobulin M response to hepatitis A virus determined by solid phase radioimmunoassay. Infect Immun 1980;28:927-936.

112. Koff RS: Seroepidemiology of hepatitis A in the United States. J Infect Dis 1995;171(Suppl 1):S19-S23.

112a. Jilg W, Bittner R, Bock HL, et al.: Vaccination against hepatitis A: comparison of different short-term immunization schedules. Vaccine 1992;10(Suppl 1): S126-S128.

112b. Goubau P, Gan Gerven V, Safary A: Effect of virus strain and antigen dose on immunogenicity and reactogenicity of an inactivated hepatitis A vaccine. Vaccine 1992;10(Suppl 1):S114-S118.

112c. Totos G, Gizaris V, Papaevangelou G: Hepatitis A vaccine: persistence of antibodies 5 years after the first vaccination. Vaccine 1997;15:1252-1253.

113. Feinstone SM, Kapikian AZ, Purcell RH: Hepatitis A: detection by immune electron microscopy of virus-like antigen associated with acute illness. Science 1973;182:1026-1028.

114. Hollinger FB, Bradley DW, Maynard JE, Dreesman GR, Melnick JL: Detection of hepatitis A viral antigen by radioimmunoassay. J Immunol 1975;115:1464-1466.

115. Fujiwara K, Yokosuka O, Ehata T, et al.: Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology 1997;26:1634-1649.

116. Hollinger FB, Dreesman GR: Hepatitis viruses. In Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM (eds.): Manual of Clinical Laboratory Immunology, 5th ed. Washington DC, American Society for Microbiology, 1997

117. Lemon SM, Gates NL, Simms TE, Bancroft WH: IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus. J Infect Dis 1981;143:803-809.

118. Noskin GA: Prevention, diagnosis, and management of viral hepatitis: a guide for primary care physicians. Arch Fam Med 1995;4:923-934.

119. Czaja AJ, Shiels MT, Taswell HF, Wood JR, Ludwig J, Chase RC: Frequency and significance of immunoglobulin M antibody to hepatitis B core antigen in corticosteroid-treated severe chronic active hepatitis B. Mayo Clin Proc 1988;63:119-125.

120. Sjogren M, Hoofnagle JH: Immunoglobulin M antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Gastroenterology 1985;89:252-258.

121. Seeff LB, Beebe GW, Hoofnagle JH, et al.: A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army. N Engl J Med 1987;316:965-970.

121a. Aoki SK, Finegold D, Kuramoto IK, et al.: Significance of antibody to hepatitis B core antiben in blood donors as determined by their serologic response to hepatitis B vaccine. Transfusion 1993;33:362-367.

121b. Draelos M, Morgan T, Schifman RB, Sampliner RE: Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. JAMA 1987;258:1193-1195.

122. Yostuyanagi H, Yasuda K, Iino S, et al.: Persistent viremia after recovery from self-limited acute hepatitis B. Hepatology 1998;27:1377-1382.

123. Cabrerizo M, Bartolome J, De Sequera P, Caramelo C, Carreno V: Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis patients and staff. J Am Soc Nephrol 1997;8:1443-1447.

124. Loriot MA, Marcellin P, Walker F, et al.: Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol 1997;27:251-258.

125. Kuhns MC, McNamara AL, Perrrilo RP, Cabal CM, Campbell CR: Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Virol 1989;27:274-281.

126. Butterworth LA, Prior SL, Buda PJ, Faoagali JL, Cooksley WG: Comparison of four methods for quantitative measurement of hepatitis B viral DNA. J Hepatol 1996;24: 686-691.

128. Zaaijer HL, ter Borg F, Cuypers HT, Hermus MC, Lelie PN: Comparison of methods for detection of hepatitis B virus DNA. J. Clin. Microbiol. 1994;32:2088-2091.

129. Kaneko S, Miller RH, Feinstone SM, et al.: Detection of serum hepatitis B virus DNA in patients with chronic hepatitis using the polymerase chain reaction assay. Proc Natl Acad Sci USA 1989;86:312-316.

130. Kessler HH, Pierer K, Dragon E, et al.: Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin Diagn Virol 1998;9:37-43.

131. Chernesky MA, Gretch D, Mushahwar IK, Swenson PD, Yarbough PO: Cumitech 18A. Laboratory diagnosis of the hepatitis viruses. Coordinating ed. S. Young. Washington DC, American Society for Microbiology, 1998.

132. Alter JH: New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992;15:340-353.

133. Brillanti S: Serum IgM antibodies to hepatitis C virus in acute and chronic hepatitis C. Arch Virol Suppl 1993;8:213-218.

134. Aach R, Stevens C, Hollinger F, et al.: Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-1329.

135. Barrera JM, Francis B, Ercilla G, et al.: Improved detection of anti-HCV in post-transfusion hepatitis by a third-generation ELISA. Vox Sang 1995;68:15-18.

136. Uyttendaele S, Claeys H, Mertens W, Verhaert H, Vermylen C: Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang 1994;66:15-18.

137. Busch M, Tobler L, Quan S, et al.: A pattern of 5-1-1 and c100-3 only on hepatitis C (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors. Transfusion 1993;33:84-88.

138. Rossini A, Gazzola GB, Ravaggi A, et al.: Long-term follow-up and infectivity in blood donors with hepatitis C antibodies and persistently normal alanine aminotransferase levels. Transfusion 1995;35:108-111.

139. Pawlotsky J, Bastie A, Pellet C, et al.: Significance of indeterminate third-generation hepatititis C virus recombinant immunoblot assay. J Clin Microbiol 1996;34:80-83.

139a. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999;29:908-914.

140. Gretch D: Diagnostic tests for hepatitis C. Hepatology 1997;26(Suppl 1): 43S-47S.

140a. Alter MJ, Margolis HS, Krawczynski K, et al.: The natural history of community acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.

141. Gretch DR, dela Rosa C, Carithers RL, Wilson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995;123:3211-329.

142. Barrera JM, Bruguera M, Ercilla MG, et al.: Persistent hepatitis C viremia after acute self-limited posttransfusion hepatitis. Hepatology 1995;21:639-644.

143. Damen M, Cuypers HTM, Zaaijer HL, et al.: International collaborative study on the second EUROHEP HCV-RNA reference panel. J Virol Meth 1995;48:175-185.

143a. Ravaggi A, Biasin MR, Infantolino D, Cariani E: Comparison of competitive and non-competitive reverse transcriptiohn-polymerase chain reaction (RT-PCR) for the quantification of hepatitis C virus (HCV) RNA. J Virol Methods 1997;65A:123-129.

143b. Lunel et al. Hepatology 1999;29:528-535.

144. National Committee for Clinical Laboratory Standards. Molecular Diagnostic Methods for Infectious Diseases (MM3-A); Approved Guideline. Wayne PA, National Committee for Clinical Laboratory Standards, 1995.

145. Davis GL, Lau JY,. Urdea MS, et al.: Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification assay: definition of optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.

146. Roth WK, Lee J-H, Ruster B, Zeuzem S: Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays. J Clin Microbiol 1996;34:261-264.

147. Lau JY, Mizokami M, Kolberg JA, et al.: Application of six hepatitis C genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995;171:282-289.

148. Rizetto M, Ponzetto A, Forzani I: Epidemiology of hepatitis delta virus: overview. Prog Clin Biol Res 1991;364:1-20.

149. Dinolfo L, Abate ML, Bertolo P, et al.: Detection of hepatitis D virus RNA in serum by a reverse transcription, polymerase chain reaction-based assay. Int J Clin Lab Res 1995;25:35-39.

150. Madejon A, Cotonat T, Bartolome J, Castillo I, Carreno V: Treatment of chronic hepatitis D infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology 1994;19:1331-1336.

151. Polish LB, Gallagher M, Fields HA, Hadler SC: Delta hepatitis: molecular biology and clinical and epidemiological features. Clin Microbiol Rev 1993;6:211-229.

152. Yarbourgh, PO, Tam AW, Gabor K, et al.: Assay development of diagnostic tests for hepatitis E. In Nishioka K, Suzuki H, Mishiro S, Oda T (eds.): Viral Hepatitis and Liver Disease. Tokyo, Japan, Springer-Verlag, 1994.

153. Mast EE, Alter MJ, Holland PV, Purcell RH: Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology 1998;27:857-861.

154. Thomas DL, Yarbough PO, Vlahov D, et al.: Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol 1997;35:1244-1247.

155. Gouvea V, Cohen SJ, Santos N, Myint KS, Hoke C, Innis BL: Identification of hepatitis E virus in clinical specimens: amplification of hydroxyapatite-purified virus RNA and restriction endonuclease analysis. J Virol Methods 1997;69:53-61.

156. Clayson ET, Myint KS, Snitbhan R, et al.: Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E. J Infect Dis 1995;172:927-933.

157. Chobe LP, Cdhadha MS, Banerjee K, Arankalle VA: Detection of HEV RNA in faeces, by RT-PCR during the epidemics of hepatitis E in India (1976-1995). J Viral Hepat 1997;4:129-133.

160. Ellis G, Goldberg DM, Spooner RJ, Ward AM: Serum enzyme tests in diseases of the liver and biliary tree. Am J Clin Pathol 1978;70:248-258.

160a. Fortson WC, Tedesco FJ, Starnes EC, Shaw CT: Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease. J Clin Gastroenterol 1985;7:502-505.

161. Borsch G, Baier J, Glocke M, Nathusius W, Gerhardt W: Graphical analysis of laboratory data in the differential diagnosis of cholestasis: a computer-assisted prospective study. J Clin Chem Clin Biochem 1988;26:509-519.

162. Rozen P, Korn RJ, Zimmerman HJ: Computer analysis of liver function tests and their interrelationship in 347 cases of viral hepatitis. Isr J Med Sci 1970;6:67-79.

162a. Mendenhall CL and the VA Cooperative Study Group on Alcoholic Hepatitis: Alcoholic hepatitis. Clin Gastroenterol 1981;10:417-441.

162b. Mihas AA, Doos WG, Spenney JG: Alcoholic hepatitis – a clinical and pathological study of 142 cases. J Chronic Dis 1978;31:461-472.

162c. Goldberg S, Mendenhall C, Anderson S, et al.: VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis – describing the population with minimal hyperbilirubinemia. Am J Gastroenterol 1986;81:1029-1034.

162d. Nissenbaum M, Chedid A, Mendenhall C, Gartside P: Prognostic significance of cholestatic alcoholic hepatitis. VA Cooperative Study Group # 119. Dig Dis Sci 1990;35:891-896.

163. Cohen JA, Kaplan MM: The SGOT/SGPT ratio – an indicator of alcoholic liver disease. Dig Dis Sci 1979;24:835-838.

163a. Stewart JS, Farrow LJ, Clifford RE, et al.: A three-year survey of viral hepatitis in West London. Q J Med 1978;47:365-84.

164. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW: Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985;122:226-233.

165. Gitlin N: Hepatitis B: diagnosis, prevention, and treatment. Clin Chem 1997;43:1500-1506.

165a. McMahon BJ, Alward WL, Hall DB, et al.: Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dise 1985;151:599-603.

166. Hoofnagel JH: Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26(Suppl 1):15S-20S.

167. Seeff LB, Wright EC, Zimmerman HJ, McCollum: VA Cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteristics of hepatitis and responsible risk factors. Am J Med Sci 1975;270:355-362.

167a. Harrison PM, O’Grady JG, Keays RT, Alexander GJ, Williams R: Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ 1990;301:964-968.

168. Gitlin N, Serio KM: Ischemic hepatitis: widening horizons. Am J Gastroenterol 1992;87:831-836.

169. Tygstrup N, Ranek L: Assessment of prognosis in fulminant hepatic failure. Semin Liv Dis 1986;6:129-137.

170. Anand A, Nightingale P, Neuberger P: Early indicators of prognosis in fulminant hepatic failure: an assessment of the King’s criteria. J Hepatol 1997;26:62-68.

171. Harrison PRm O’Grady JG, Keays RT, Alexander GJ, Williams R: Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ 1990;301:964-966.

172. Dymock IW, Tucker JS, Woolf IL, et al: Coagulation studies as a prognostic index in acute liver failure. Br J Haematol 1975;29:385-395.

173. Horak W, Waldram R, Murray-Lyons IM, et al.: Kinetics of (14C) cholic acid in fluminant hepatic failure: a prognostic test. Gastroenterology 1976;71:809-813.

173a. O’Grady JG, Alexander GJM, Hayllar KM, Williams R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439-445.

173b. Munoz SJ: Prothrombin time in fulminant hepatic faliure. Gastroenterology 1991;100:1480-1481.

174. London WT, Evans AA: The epidemiology of hepatitis viruses B, C, and D. Clin Lab Med 1996;16:251-171.

175. Fry SW, Seeff LB: Hepatotoxicity of analgesics and antiinflammatory agents. Gastroenterol Clin North Am 1995;24:875-905.

176. Zimmerman HJ, Maddrey WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995;22:767-773.

176a. Silva MO, Roth D, Reddy KR, Fernandez JA, Albores-Saavedra J, Schiff ER: Hepatic dysfunction accompanying acute cocaine intoxication. J Hepatol 1991;12:312-315.

177. Johnson RD, O’Connor ML, Kerr RM: Extreme serum elevations of aspartate aminotransferase. Am J Gastroenterol 1995;90:1244-1245.

178. Shilsky ML: Wilson disease: genetic basis of copper toxicity and natural history. Semin Liv Dis 1996;16:83-95.

179. Steindl, P, Ferenci P, Dienes HP, et al.: Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 1997;113:212-218.

180. Berman DH, Leventhal RI, Gavaler JS, Cadoff EM, Van Thiel DH: Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 1991;100:1129-1134.

181. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW: The Wilson disease gene is a putative copper transporting P-type ATP-ase similar to the Menkes gene. Nature Genet 1993;5:327-337.

182. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW: The Wilson disease gene: spectrum of mutations and their consequences. Nature Genet 1995;9:210-217.

183. Crapper RM, Bhathal PS, Mackay IR, Frazer IH: "Acute" autoimmune hepatitis. Digestion 1986;34:216-225.

184. Amontree JS, Stuart TD, Bredfeldt JE: Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol 1989;11:303-307.

185. Davis GL, Czaja AJ, Baggenstoss AH, Taswell HF: Prognostic and therapeutic implications of extreme aminotransferase elevation in chronic hepatitis. Mayo Clin Proc 1982;57:303-309.

186. Johnson PJ, McFarlane IG, Alvarez F, et al.: Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1008.

187. Czaja AJ: Diagnosis and therapy of autoimmune liver disease. Med Clin North Am 1996;80:973-994.

187aa. Horwitz CA, Burke MD, Grimes P, Tombers J: Hepatic function in mononucleosis induced by Epstein-Barr virus and cytomegalovirus. Clin Chem 1980;26:243-246.

187a. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS: Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983;84:216-219.

187b. Yuki N, Hayashi N, Moribe T, et al.: Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies. Hepatology 1997;25:439-444.

188. Clermont RJ, Chalmers TC: The transaminase tests in liver disease. Medicine 1967;46:197-207.

189. Scheig R: Evaluation of tests used to screen patients with liver disorders. Prim Care 1996;23:551-60.

190. Tong MJ, el-Farra NS, Crew MI: Clinical manifestations of hepatitis A. Recent experience in a community teaching hospital. J Infect Dis 1995;171 Suppl 1:S15-S18.

190a. Sjogren MH, Tanno H, Foy O, et al.: Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-226.

190b. Glikson M, Aalun E, Oren R, Tur-Kapsa R, Shouval D: Relapsing hepatitis A: review of 14 cases and literature survey. Medicine 1992;71:140-23.

190c. Inglesby TV, Rai R, Astemborski J, et al.: A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use. Hepatology 1999;29:590-596.

191. Weiss JS, Gautman A, Lauff JJ, et al.: The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983;309:147-150.

192. Van Hootegem P, Fevery J, Blanckaert N: Serum bilirubins in hepatobiliary disease: comparison with other liver function tests and changes in the postobstructive period. Hepatology 1985;5:112-117.

193. Adachi Y, Inufusa H, Yamashita M, et al.: Serum bilirubin fractionation using multilayer film method in hepatobiliary diseases in comparison with high performance liquid chromatography. Gastroenterol Jpn 1987;22:633-639.

193a. Gordon SC, Reddy KR, Schiff L, Schiff ER: Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med 1984;101:635-637.

194. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.

195. Niederau C, Lange S, Heintges T, et al.: Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998;28:1687-1695.

196. Seeff LB: Natural history of hepatitis C. Hepatology 1997;26(Suppl 1):21S-28S.

197. Van Ness MM, Diehl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-478.

198. Alter HJ, Conry-Cantilena C, Melpolder J, et al.: Hepatitis C in asymptomatic blood donors. Hepatology 1997;26(Suppl 1):29S-33S.

199. Mathurin P, Moussali J, Cadranel J-F, et al.: Slow progression rate of fibrosis in hepatitis C patients with persistently normal alanine aminotransferase activity. Hepatology 1998;27:568-572.

199a. Kenny-Walsh E, for the Irish Hepatology Research Group: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-1233.

200. Marcellin P, Levy S, Erlinger S: Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology 1998;26(Suppl 1):133S-136S.

201. San Giovani A, Spinzi GC, Ceriani R, et al.: Randomized control trial of HCV healthy carriers with interferon. Hepatology 1995;22:290A.

202. Centers for Disease Control and Prevention: Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No.RR-19), 1-39.

203. Quinn PG, Johnston DE: Detection of chronic liver disease: costs and benefits. Gastroenterologist 1997;5:58-77.

204. Sampliner RE, Deluk D, Harrow EJ: Blood donors with elevated alanine aminotransferase levels – persistence of elevation and liver histology. Gastroenterology 1983;84:1394.

205. Hultcrantz R, Glaumann H, Lindberg G, Nilsson LH: Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986;21:109-113.

206. Friedman LS, Dienstag JL, Watkins E, et al.: Evaluation of blood donors with elevated serum alanine aminotransferase levels. Ann Intern Med 1987;107:137-144.

207. Hay JE, Czaja AJ, Rakela J, Ludwig J: The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989;9:193-197.

208. Kundrotas LW, Clement DJ: Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors. Dig Dis Sci 1993;38:2145-2150.

209. Serafty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R: Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995;21:725-729.

210. Cauza E, Maier-Dobersberger T, Polli C, Kaserer K, Kramer L, Ferenci P: Screening for Wilson’s disease in patients with liver diseases by serum ceruloplasmin. J Hepatol 1997;27:358-362.

211. Adler M, Schaffner F: Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.

212. Ludwig J, Viggiano TR, McGill DB, Ott BJ: Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.

213. Sheth SG, Gordon FD, Chopra S: Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-145.

214. Bacon BR, Farahvash MJ, Janney CJ, Neuschwander-Tetri BA: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.

214a. Sorbi D, Boynton J, Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022.

215. Cortez Pinto H, Baptista A, Camilo MA, Valenta A, Saragoca A, Sarneiro de Moura M: Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179.

215a. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-1413.

216. McLaren CE, Gordeuk VR, Looker AC, et al.: Prevalence of heterozygotes for hemochromatosis in the white population of the United States. Blood 1995;86:2021-2027.

217. Feder JN, Gnirke A, Thomas W, et al.: A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.

218. Crawford DH, Jazwinska EC, Cullen LM, Powell LW: Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation. Gastroenterology 1998;114:1003-1008.

219. Milman N, Albeck MJ: Distinction between homozygous and heterozygous subjects with hereditary haemochromatosis using iron status markers and receiver operating characteristic (ROC) analysis. Eur J Clin Chem Clin Biochem 1995;33:95-98.

220. Witte DL: Mild liver enzyme abnormalities: eliminating hemochromatosis as cause. Cclin Chem 1997;53:1535-1538.

221. McDonnell SM, Phatak PD, Felitti V, Hover A, McLaren GD: Screening for hemochromatosis in primary care settings. Ann Intern Med 1998;129:962-970.

222. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH: Molecular medicine and hemochromatosis: at the crossroads. Gastroenterology 1999;116:193-207.

223. Bassett ML, Legett BA, Halliday JW, Webb S, Powell LW: Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers. J Hepatol 1997;27:517-524.

224. Burke W, Thomson E, Khoury MJ, et al.: Hereditary hemochromatosis – gene discovery and its implications for population-based screening. JAMA 1998;280:172-178.

225. Cogswell ME, McDonnell SM, Khoury MJ, Franks AL, Burke W, BrittenhamG: Iron overload, public health, and genetics: evaluating the evidence for hemochromatosis screening. Ann Intern Med 1998;129:971-999.

226. Witte DL, Crosby WH, Edwards CQ, Fairbanks VG, Mitros FA: Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996;245:139-200.

227. Adams PC, Gregor JC, Kertesz AE, Valberg LS: Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995;109:177-188.

228. Gibbs K, Walshe JM: A study of the caeruloplasmic concentrations found in 75 patients with Wilson’s disease, their kindreds, and various control groups. Q J Med 1979;48:447-463.

229. Sass-Korstak A, Bearn AG: Hereditary disorders of copper metabolism. In Stanbury JB, Wyngaarden JB, Fredrickson DS (eds): The metabolic basis of inherited disease, 4th Ed. New York: McGraw Hill, 1978, p. 1098-1126.

230. Scheinberg JH, Sternlieb I: Wilson’s Disease. Philadelphia, W.B. Saunders, 1984, p. 17-24.

231. Dufour J-F, Kaplan MM: Muddying the water: Wilson’s disease challenges will not soon disappear. Gastroenterology 1997;113:348-350.

232. Czaja AJ, Carpenter HA, Manns MP: Antibodies to soluble liver antigen, P450IID5, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993;105:1522-1528.

233. Czaja AJ: Autoimmune hepatitis: evolving concepts and treatment strategies. Dig Dis Sci 1995;40:435-456.

234. Czaja AJ, Magrin S, Fabiano C, et al.: Hepatitis C virus infection as a deterinant of behavior in type I autoimmune hepatitis. Dig Dis Sci 1995;40:33-40.

235. Czaja AJ, Taswell HF, Rakela J, Rabe D: Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis. Gastroenterology 1992;102:1675-1679.

236. Carell RW, Jeppson JQ, Laurell CB: Structure and variation of human alpha-1-antitrypsin. Nature 1982;298:239-334.

237. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W: Alpha-1-antitrypsin deficiency and liver disease. Dig Dis 1994;12:139-149.

238. Sveger T: The natural history of liver disease in alpha-1-antitrypsin deficient children. Acta Paediatr Scand 1988;77:847-851.

239. Carlson J, Eriksson S: Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol 1985;20:835-842.

240. Graziadel IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK: Increased risk of chronic liver failure in adults with heterozygous a 1-antitrypsin deficiency. Hepatology 1998;28:1058-1063.

241. Fisher RL, Taylor L, Sherlock S: a -1-antitrypsin deficiency in liver disease: the extent of the problem. Gastroenterology 1976;71:646-651.

242. Morin T, Feldman G, Benhamou JP: Heterozygous alpha1-antitrypsin deficiency and cirrhosis in adults, a fortuitous association. Lancet 1975;i:250-251.

243. Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W.: High prevalence of viral infection in adults with homozygous and heterozygous alpha1-antitrypsin deficiency and chronic liver disease. Ann Intern Med 1992;117:641-645.

244. Hodges JR, Millward-Sadler GH, Baarbatis C, Wright R: Heterozygous MZ alpha1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis. N Engl J Med 1981;304:557-560.

245. Haber MM, West AB, Haber AD, Reuben A: Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-1257.

246. Healey CJ, Chapman RWG, Fleming KA: Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases. Gut 1995;37:274-278.

247. McCormick SE, Goodman ZD, Maydonovitch CL, Sjogren MH: Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C. Am J Gastroenterol 1996;91:1516-1522.

248. Perrillo RP: The role of liver biopsy in hepatitis C. Hepatology 1997;26(Suppl 1):57S-61S.

248a. Pontisso P, Bellati G, Brunetto M, Et al.: Hepatitis C virus profiles in chronically infected individuals: do they relate to disease activity? Hepatology 1999;29:585-589.

248b. Camma C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L: Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized clinical trials. Am J Gastroenterol 1999;94:581-595.

249. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM: Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am J Gastroenterol 1996;91:2323-2328.

250. Heijtink RA, Kruining J, Honkoop P, et al.: Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B. J Med Virol 1997;53:282-287.

251. Bernard F, Raymond G, Willems B, Villeneuve JP: Quantitative assessment of serum hepatitis B e antigen, IgM hepatitis B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B. J Viral Hepat 1997;4:265-272.

252. Pawlotsky JM, Batiste A, Lonjon I, et al.: What technique should be used for routine detection and quantification of HBV DNA in clinical samples. J Virol Methods 1997;65:245-253.

253. Management of Hepatitis C. NIH Consens Statement 1997;15:1-41.

254. Davis GL, Lau JYN: Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997;26(Suppl 1):122S-127S.

255. Davis GL, Balart LA, Schiff ER, et al.: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized controlled trial. N Engl J Med 1989;321:1501-1506.

256. Lindsay KL, Davis GL, Schiff ER, et al.: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatology 1996;24:1034-1040.

257. Kasahara A, Hayashi N, Mochizuki M, et al.: Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-1402.

258. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.

259. Poynard T, Marcellin S, Lee SS, et al.: Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.

260. Nagayama Y, Ohta K, Tsuruta M, et al.: Exacerbation of thyroid autoimmunity by interferon a treatment in patients with chronic viral hepatitis: our studies and review of the literature. Endocr J 1994;41:565-572.

261. Davis BH, Kresina TF: Hepatic Fibrogenesis. Clin Lab Med 1996;16:361-375.

262. Oberti F, Valsesia E, Pilette C, et al.: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997;113:1609-1616.

263. Kropf J, Gressner AM, Negwer A: Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases. Clin Chem 1988;34:2026-2030.

264. Tsutsumi M, Takase S, Urashima S, Ueshima Y, Kawahara H, Takada A: Serum markers for hepatic fibrosis in alcoholic liver disease: which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase. Alcohol Clin Exp Res 1996;20:1512-1517.

265. Yamada S, Suou T, Kawasaki H, Yoshikawa N: Clinical significance of serum 7S collagen in various liver diseases. Clin Biochem 1992;25:467-470.

266. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J: Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-563.

267. Korner T, Kropf J, Gressner AM: Serum laminin and hyaluronan in liver cirrhosis: markers with high prognostic value. J Hepatol 1996;25:684-688.

268. Fabris C, Falleti E, Federico E, Toniutto P, Pirisi M: A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis. Ann Clin Biochem 1997;34:151-155.

269. Sopena B, Martinez-Vazquez C, Fernandez-Rodriguez CM, et al.: Serum angiotensin converting enzyme and C4 protein of complement as a combined diagnostic index in alcoholic liver disease. Liver 1996;16:305-308.

270. Falleti E, Pirisi M, Gabris C, et al.: Circulating standard CDP9D isoform in patients with liver disease: relationship with other soluble adhesion molecules and evaluation of diagnostic usefulness. Clin Biochem 1997;30:69-73.

271. Trinchet J-C: Clinical use of serum markers of fibrosis in chronic hepatitis. J Hepatol 1995;22(Suppl 2):89-95.

272. Williams AL, Hoofnagle JH: Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739.

273. Sheth SG, Glamm SL, Gordon FD, Chopra S: AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroneterol 1998;93:44-48.

273a. Goldstein NS, Blue DE, Hankin R, et al.: Serum a -fetoprotein levels in patients with chronic hepatitis C – relationship with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Am J Clin Pathol 1999;111:811-816.

273b. Bayati N, Silverman AL, Gordon SC: Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998;93:2452-2456.

274. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-750.

275. Fattovich F, Giustina G, Schalm SW, et al..: Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology 1995;21:77-82.

276. Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a restrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.

277. Zaman SN, Johnson PJ, Williams R: Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas. Cancer 1990;65:1607-1610.

278. McMahon BJ, London T: Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991;83:916-919.

279. Riegler JL: Preneoplastic conditions of the liver. Sem Gastrointest Dis 1996;7:74-87.

280. Pateron D, Ganne N, Trinchet JC, et al.: Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1995;22:708-709.

281. Sherman M, Peltekian KM, Lee C: Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American population. Hepatology 1995;22:432-438.

282. Villeneuve J-P, Desrochers M, Infante-Rivard C, et al.: A long-term follow-up study of asymptomatic hepatitis B surface antigne-positive carriers in Montreal. Gastroenterology 1994;108:1000-1005.

283. Colombo M, de Franchis R, Del Ninno E, et al.: Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680.

284. Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.

285. Cottone M, Turri M, Caltagirone M, et al.: Screening for hepatocellular carcinoma in patients with Child’s A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. J Hepatol 1994;21:1029-1034.

286. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.

287. Sarasin FP, Giostra E, Hadengue A: Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996;101:422-434.

288. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology 1998;27:273-278.

289. Sheu JC, Sung JL, Chen DS, et al.: Growth rate of asymptomatic hepatocellular carcinoma and its clinical significance. Gastroenterology 1983;89:259-266.

290. Cottone M, Virdone R, Fusco G, et al.: Asymptomatic hepatocellular carcinoma in Child’s A cirrhosis. Gastroenterology 1989;96:1566-1571.

291. Barbara L, Benzi G, Gaiani S, et al.: Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992;16:132-137.

292. Fujiyama S, Morishita T, Hashiguchi O, Sato T: Plasma abnormal prothrombin (des-g -carboxy prothrombin) as a marker of hepatocellular carcinoma. Cancer 1988;61:1621-1628.

293. Liebman HA, Furie BC, Tong MJ, et al.: Des-g -carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.

294. Aoyagi Y, Oguro M, Yanagi M, et al.: Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma. Cancer 1996;77:1782-1796.

295. Izuno K, Fujiyama S, Yamasaki K, Sato M, Sato T: Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology 1995;42:387-393.

296. Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H: The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82:1643-1648.

297. Lefrere J-J, Gozin D, Soulier J-P, et al.: Specificity of increased des-gamma-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection. J Hepatol 1987;5:27-29.

298. Sakon M, Monden M, Gotoh M, et al.: The effects of vitamin K on the generation of des-g -carboxy prothrombin in patients with hepatocellular carcinoma. Am J Gastroenterol 1991;86:339-345.

298a. Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K: Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gatroenterol 1999;94:650-654.

299. Shiraki K, Takase K, Tameda Y, et al.: A clinical study of lectin-reactive alpha-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology 1995;22:802-807.

300. Lu Y, Lu Q, Chen HL: Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase. J Exp Clin Cancer Res 1997;16:75-80.

301. Yao D-F, Huang Z-W, Chen S-Z, et al.: Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specifid bands of serum g -glutamyltransferase. Am J Clin Pathol 1998;110:743-749.